Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DAYPRO ALTA vs IBU-TAB 200
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Rheumatoid arthritis,Osteoarthritis,Juvenile idiopathic arthritis,Ankylosing spondylitis (off-label),Acute gout (off-label)
Pain,Fever,Inflammation,Dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Migraine
Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
50-65 hours (mean 57 hours); clinically significant accumulation occurs with multiple dosing, requiring dose adjustment in elderly and renal impairment.
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Primarily hepatic via cytochrome P450 (CYP) 2C9 and CYP2C8; minor metabolism via glucuronidation. Metabolites are inactive.
Hepatic metabolism primarily via CYP2C9.
Renal: 85% (60-90% as oxaprozin glucuronide and 5-10% as unchanged oxaprozin); Fecal: <5%; Biliary: negligible.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
>99.5% bound to albumin.
99% bound to albumin.
0.15-0.25 L/kg; low Vd indicates extensive plasma protein binding and limited tissue distribution.
0.1-0.2 L/kg (low Vd, confined to plasma and interstitial fluid).
Oral: approximately 100% (well absorbed with no significant first-pass metabolism).
Oral: 80-100% (with food may reduce rate).
For patients with creatinine clearance (Cr Cl) of 50-79 m L/min: no dose adjustment is generally required, but monitor for adverse effects. For Cr Cl 30-49 m L/min: reduce dose by 50% or use 600 mg once daily. For Cr Cl <30 m L/min: use is contraindicated. End-stage renal disease (ESRD): avoid use.
e GFR 30-59 m L/min: reduce dose by 50% or increase interval to every 8-12 hours; e GFR <30 m L/min: avoid use or maximum 400 mg/day.
Child-Pugh Class A (mild impairment): no dose adjustment needed. Child-Pugh Class B (moderate impairment): reduce dose by 50% or use 600 mg once daily; monitor closely. Child-Pugh Class C (severe impairment): use is contraindicated. No specific studies; caution advised.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not approved for pediatric use. Safety and efficacy have not been established in patients under 18 years. Avoid use in children and adolescents unless under expert guidance and with caution.
6 months to 12 years: 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day. For fever or pain: 5 mg/kg per dose for temperatures <102.5°F, 10 mg/kg per dose for higher fever.
Elderly patients (≥65 years) are at increased risk for NSAID-related adverse effects, including GI bleeding, renal impairment, and cardiovascular events. Initiate therapy at the lowest effective dose (e.g., 600 mg once daily) and monitor renal function, blood pressure, and for signs of GI toxicity. Avoid use if possible in patients with high cardiovascular risk or history of GI ulceration.
Start at lowest effective dose (200 mg every 6-8 hours); maximum 400 mg/day due to increased risk of renal and GI adverse effects.
Cardiovascular risk: NSAIDs may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Gastrointestinal risk: NSAIDs increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal. These events can occur at any time without warning.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk.
Cardiovascular thrombotic events (MI, stroke),Gastrointestinal bleeding, ulceration, perforation,Renal toxicity (elevated creatinine, nephrotoxicity),Hepatic effects (transaminase elevations, rare severe hepatotoxicity),Hypertension exacerbation,Fluid retention and edema,Anaphylactoid reactions,Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome),Premature closure of ductus arteriosus in pregnancy,Hematologic effects (anemia, bleeding)
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, anaphylactoid reactions, hepatic effects, asthma exacerbation, pregnancy avoidance (third trimester).
Hypersensitivity to oxaprozin or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In setting of coronary artery bypass graft (CABG) surgery,Advanced renal disease,Pregnancy (third trimester) due to risk of preterm closure of ductus arteriosus and oligohydramnios
Hypersensitivity to ibuprofen or NSAIDs, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of coronary artery bypass graft (CABG) surgery, severe renal impairment, active peptic ulcer disease.
May be taken with food or milk to minimize gastrointestinal irritation. Avoid alcohol due to increased risk of GI bleeding. No specific food restrictions otherwise.
Avoid alcohol. Take with food or milk to minimize gastric irritation. Grapefruit juice may modestly increase ibuprofen absorption but clinical significance is low; no strict restriction. Administer with a full glass of water.
First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimester: Avoid after 30 weeks due to premature closure of ductus arteriosus and oligohydramnios. DAYPRO ALTA (oxaprozin) is contraindicated in third trimester.
First trimester: Avoid due to potential increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Use only if clearly needed; no clear teratogenic risk but may cause premature closure of ductus arteriosus. Third trimester: Contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal renal impairment.
Oxaprozin is excreted in human milk; M/P ratio is approximately 0.5. Due to potential adverse effects on infant, caution is advised. Use only if benefit outweighs risk, consider alternative agents.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01). Considered compatible with breastfeeding; use lowest effective dose for shortest duration. Monitor infant for rash, gastrointestinal effects, or drowsiness.
In pregnancy, oxaprozin clearance may increase; however, no specific dose adjustment is recommended. Use lowest effective dose for shortest duration during first and second trimesters. Avoid in third trimester.
No specific dose adjustment recommended for pregnancy-related pharmacokinetic changes. However, due to increased plasma volume and renal clearance, therapeutic efficacy may be reduced; use lowest effective dose. Avoid in third trimester.
Daypro Alta (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~40-50 hours) allowing once-daily dosing. Monitor for GI bleeding, renal impairment, and cardiovascular events. Use with caution in elderly and those with renal insufficiency. Avoid in patients with aspirin-sensitive asthma or NSAID allergy.
Ibuprofen (IBU-TAB 200) is an NSAID; avoid in patients with Cr Cl <30 m L/min. Dose adjustment not needed for mild hepatic impairment but contraindicated in severe hepatic disease. Use lowest effective dose for shortest duration to minimize renal and GI risk. Can mask signs of infection; monitor for fever in at-risk patients. Not recommended in late pregnancy (after 30 weeks) due to risk of premature ductus arteriosus closure.
Take with food or milk to reduce stomach upset.,Do not take other NSAIDs or aspirin while on this medication.,Report any signs of stomach bleeding (black stools, coffee-ground vomit), chest pain, or swelling.,Avoid alcohol as it increases GI bleeding risk.,Tell your doctor about all medications, especially blood thinners and diuretics.
Take with food or milk to reduce gastrointestinal upset.,Do not exceed 1200 mg per day without consulting your doctor.,Avoid drinking alcohol while taking this medication as it increases the risk of stomach bleeding.,If you have high blood pressure, heart disease, or kidney disease, use only under medical supervision.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of allergic reaction (rash, swelling, difficulty breathing).,Do not take with other NSAIDs (e.g., aspirin, naproxen) unless directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DAYPRO ALTA vs IBU-TAB 200, answered by our medical review team.
DAYPRO ALTA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. IBU-TAB 200 is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DAYPRO ALTA and IBU-TAB 200 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DAYPRO ALTA is: Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.. The standard adult dose of IBU-TAB 200 is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DAYPRO ALTA and IBU-TAB 200 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DAYPRO ALTA is classified as Category C. First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimes. IBU-TAB 200 is classified as Category C. First trimester: Avoid due to potential increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Use only if clearly needed; n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.